INTRODUCTION {#S1}
============

The adult mammalian brain continuously produces new neurons in two discrete regions, the subventricular zone (SVZ) lining the ventricles and the dentate gyrus (DG) of the hippocampus ([@R5]; [@R16]). In rodents, hippocampal neurogenesis is enhanced by external factors, including an enriched environment and voluntary running exercise ([@R11]; [@R71]). A decline in hippocampal neurogenesis occurs with age and may underlie cognitive and mood alterations associated with aging and Alzheimer's disease ([@R44]; [@R57]).

Hippocampal neurogenesis occurs within the subgranular zone (SGZ) of the DG and is initiated by neural stem cells (NSCs), which undergo a series of divisions to generate new granular layer interueurons that integrate into the hippocampal circuitry ([@R40]). NSCs include a quiescent population, which are radial glia-like cells (RGLs) (or type-1 cells) that are characterized by the expression of Nestin, GFAP, Sox2, and Hes5 ([@R8]; [@R24]; [@R51]; [@R67]). NSC activation is upon Ascl1 regulation ([@R6]) and leads to generate proliferative progenitors, known as intermediate progenitors (IPCs), which in turn give rise to committed neuronal progenitors (neuroblasts). Whereas the steps of hippocampal neuron formation have been well characterized ([@R9]; [@R40]), the molecular mechanisms controlling this cellular progression remain poorly understood.

Several signaling pathways are known to maintain hippocampal NSC quiescence through inhibition of cell proliferation. Conditional disruption of the genes encoding BMP2 and 4, sFRP3, Notch/RBP-J, and REST in RGLs all result in rapid activation of NSC division, leading to a transient increase in IPC numbers and production of new adult hippocampal neurons ([@R19]; [@R28]; [@R37]; [@R55]). In contrast to these repressors of NSC activation, only a few positive regulators of NSC division and progenitor cell production are known. These include sonic hedgehog/smoothened and BDNF/TrkB, but both of these signaling pathways are also active in other subpopulations of the hippocampal niche ([@R47]; [@R53]). Identification of NSC-selective positive regulators should allow prolonging or enhancing neurogenesis during aging and improve the efficacy of NSC-based repair therapies, especially in older patients.

Vascular endothelial growth factors (VEGFs) and their high-affinity tyrosine kinase receptors (VEGFRs) are potent regulators of the growth and maintenance of vascular and neural cells ([@R20]; [@R72]). In the hippocampus, VEGF-A increases angiogenesis, neurogenesis, and neuronal plasticity ([@R18]; [@R26]; [@R48]). However, it is not clear whether VEGF-A enhances neurogenesis directly, through its receptors VEGFR1 and 2 on neural cells, or indirectly, through factors released from newly formed blood vessels. The related growth factor VEGF-C is a potent regulator of lymphangiogenesis ([@R50]). VEGF-C also induces angiogenesis but only weakly, as expression of its receptor VEGFR3 is mainly restricted to tip cells at the extremities of growing blood vessels ([@R68]). In the brain, we have previously shown that VEGF-C stimulates neurogenesis via direct cell-autonomous actions of VEGFR3 in neural cells. Deletion of *Vegf-c* impairs neural development in both *Xenopus* and mouse embryonic brains, and conditional deletion of *Vegfr3* within NSCs affects neurogenesis in the adult mouse SVZ ([@R12]; [@R45]). We hypothesized that VEGF-C-VEGFR3 signaling might affect hippocampal NSCs in mice and humans, thereby controlling neurogenesis.

Here, we examined the role of VEGFR3 and its mechanism of action in adult hippocampal NSCs. We show that the VEGF-C/ VEGFR3 pathway is a positive signal that selectively promotes NSC activation and conversion into progenitor cells in mice. Moreover, VEGFR3 signaling is conserved in human NSCs where VEGF-C activates ERK- and AKT-signaling pathways. Taken together, these data identify VEGF-C/VEGFR3 as a novel signaling pathway in mammalian NSCs that may be targeted therapeutically to improve neurogenesis.

RESULTS {#S2}
=======

*Vegfr3* and *Vegf-c* Expression in the Hippocampal DG {#S3}
------------------------------------------------------

We characterized the expression of *Vegfr3* in the adult hippocampus using *Vegfr3::YFP* BAC-transgenic mice ([@R12]). YFP labeled capillaries and neural cells localized along the SGZ ([Figure 1A](#F1){ref-type="fig"}). Flow cytometric analysis of dissociated DG cells confirmed that 16% of neural cells (CD31^−^ non-endothelial cells) were YFP-expressing cells, hereafter referred to as *Vegfr3^YFP^* cells ([Figure 1B](#F1){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). Quantitative RT-PCR (qRT-PCR) showed that *Vegfr3* transcripts are highly enriched in *Vegfr3^YFP^* cells compared to DG neural cells, whereas lower levels of the two other VEGFR family members *Vegfr1* and *Vegfr2* were found in *Vegfr3^YFP^* cells ([Figure 1C](#F1){ref-type="fig"} and [S1B](#SD1){ref-type="supplementary-material"}). qRT-PCR also showed enrichment of ligand *Vegf-c* transcripts in *Vegfr3^YFP^* cells, suggesting possible autocrine VEGF-C/VEGFR3 signaling in these cells ([Figure S1B](#SD1){ref-type="supplementary-material"}). In addition, prominent VEGF-C expression was seen in DG cells surrounding the SGZ by X-gal staining of *vegfc*^LacZ+^ knockin mice and antibody staining ([Figure 1D and 1E](#F1){ref-type="fig"}), indicative of possible paracrine VEGF-C signaling to *Vegfr3^YFP^* cells.

To examine whether this ligand-receptor system functioned in hippocampal neurogenesis, we determined which type of neural cells expressed VEGFR3. About half of *Vegfr3^YFP^* cells (55%) exhibited a RGL morphology characteristic of NSCs (type-1 a) and stained positive for GFAP, Nestin, or BLBP radial glia markers ([Figure 1F--1H](#F1){ref-type="fig"} and [S1C](#SD1){ref-type="supplementary-material"}). Almost all *Vegfr3^YFP^* RGL cells expressed GFAP (99%), including a 17% subpopulation that lacked Nestin expression. Previous reports showed that GFAP^+^/Nestin^−^ RGL cells are quiescent NSCs and suggested that GFAP^+^/Nestin^+^ RGL cells are activated NSCs ([@R15]), which would indicate that *Vegfr3^YFP^* RGL cells include both quiescent and activated NSCs. The other 45% of *Vegfr3^YFP^* cells lacked radial processes ([Figure 1G](#F1){ref-type="fig"}). Less than 10% of those cells exhibited weaker YFP and stained for the IPC markers Ascl1 and Tbr2, and the rest included S100β^+^ astrocytes (15%) and non-radial Tbr2^−^ cells that may correspond to non-radial NSCs (20%). DCX^+^ neuroblasts as well as postmitotic interneurons were excluded from the *Vegfr3^YFP^* population ([Figure 1F, 1H](#F1){ref-type="fig"}, and [S1C](#SD1){ref-type="supplementary-material"}). Flow cytometric analysis of *Vegfr3^YFP^* cells confirmed that they include a majority of S100β^+^/Glast^+^/GFAP^+^ astroglial cells (65%--70%) and Sox2^+^ (50%) cells ([Figure S1D; Table S1](#SD1){ref-type="supplementary-material"}). RNA-sequencing analysis (RNA-seq) also showed enrichment of transcripts encoding NSPC markers in *Vegfr3^YFP^* cells, and specific expression of *GFAP, Nestin, Blbp, Ascl1, Tbr2*, and *Sox2* in *Vegfr3^YFP^* cells was confirmed by qRT-PCR and flow cytometric analysis ([Figures S1E and S2A; Table S2](#SD1){ref-type="supplementary-material"}).

Analysis of proliferation showed that *Vegfr3^YFP^* RGL cells are mainly quiescent (Ki67^−^) whereas non-radial *Vegfr3^YFP^* cells include a few dividing cells (5% Ki67^+^; [Figure 1l](#F1){ref-type="fig"}). Following a short BrdU-pulse (3 hr) to label proliferating NSCs and IPCs, 60% of BrdU^+^ cells were *Vegfr3^YFP^* cells ([Figure 1J and 1K](#F1){ref-type="fig"}). Altogether, these data show that *Vegfr3* expression characterizes NSCs and declines in neural progenitor cells in the adult hippocampal SGZ ([Figure 1L](#F1){ref-type="fig"}).

VEGF-C/VEGFR3 Signaling Activates Hippocampal NSCs In Vitro {#S4}
-----------------------------------------------------------

To test the stem cell properties of *Vegfr3^YFP^* cells, we sorted *Vegfr3^YFP^* and *Vegfr3^YFP-negative^* DG cells and analyzed their ability to form neurospheres, self-renew, and differentiate into neural cell types in vitro ([Figure 2](#F2){ref-type="fig"}). We found that neurospheres formed exclusively from *Vegfr3^YFP^* cells, but not from the fraction of *Vegfr3^YFP-negative^* cells, which establishes that *Vegfr3^YFP^* cells are NSCs ([Figure 2A](#F2){ref-type="fig"}). Neurospheres derived from *Vegfr3^YFP^* cells were able to self-renew for at least six passages, confirming the presence of NSCs with *long-term* self-renewal capacity ([Figure 2B](#F2){ref-type="fig"}). *Vegfr3^YFP^* neurosphere cells transferred onto Matrigel differentiated into Tuj1^+^ neurons (13%) and GFAP^+^ astrocytes (71 %) but rarely into O4^+^ oligodendrocytes (0.9%), which is consistent with previous reports showing that DG NSCs generate only very few oligodendroglial cells ([@R8]; [Figure 2C](#F2){ref-type="fig"}). *Vegfr3^YFP^* cells are therefore NSCs, which maintain self-renewal and multilineage differentiation capacities.

Addition of recombinant VEGF-C (50 ng/ml) had no effect on cell survival ([Figure 2D](#F2){ref-type="fig"}). However, VEGF-C-stimulated *Vegfr3^YFP^* cells generated more neurospheres ([Figure 2E](#F2){ref-type="fig"}). The activation of *Vegfr3^YFP^* cells by VEGF-C was blocked by treatment with a blocking antibody against VEGFR3 (31C1), indicating that the response to VEGF-C is VEGFR3 dependent ([Figure 2E](#F2){ref-type="fig"}).

To get a molecular readout of VEGF-C action on hippocampal NSCs, we performed RNA-seq. As shown in [Figure S2B and Table S2B](#SD1){ref-type="supplementary-material"}, VEGF-C-treated *Vegfr3^YFP^* cells, but not *Vegfr3^YFO-negative^* cells, strongly upregulated mRNA expression of regulators of the G1-S transition, such as cyclin D/E and cyclin-dependent kinases Cdk1/2, and of factors regulating chromosomal DNA replication. Furthermore, VEGF-C stimulation appears to drive NSCs from their quiescent state toward a proliferating progenitor state. In VEGF-C-treated cells, the expression of NSC markers such as Notch1/2 ([@R1]), Hes5 ([@R36]), Ctnnb1 (β1-catenin) ([@R49]), Bmpr1 (bone morphogenetic protein receptor) ([@R55]), Mhi1/2 (Mushashi1/2) ([@R58]), Bmi-1 ([@R25]), and Rest ([@R2]) are downregulated whereas the expression of progenitor cell markers Ascl1 ([@R41]; [@R52]), Sox21 ([@R54]), and Numb ([@R3]; [@R60]) are upregulated ([Figure S2B; Table S2B](#SD1){ref-type="supplementary-material"}). To confirm the effect of VEGF-C on cell cycle progression, we analyzed the cell cycle activity of *Vegfr3^YFP^* cells. After overnight culture in the presence or absence of VEGF-C, cells were stained with *Pyronin Y/Hoechst* 33342 and analyzed by flow cytometry ([Figure 2F](#F2){ref-type="fig"}). VEGF-C treatment of *Vegfr3^YFP^* cells, but not of *Vegfr3^YFP-negative^* cells, promotes a significant increase of cells *in G1 phase* ([Figure 2F](#F2){ref-type="fig"}). Taken together, these data demonstrate that VEGF-C/VEGFR3 signaling in NSCs initiates cell cycle entry and conversion of quiescent cells into proliferating progenitor cells.

Maintenance of Hippocampal Neurogenesis In Vivo Requires VEGFR3 {#S5}
---------------------------------------------------------------

We next investigated consequences of inducible *Vegfr3* deletion in hippocampal NSCs in vivo, using *Glast^CreERT2^* to delete *Vegfr3^flox/flox^* allele (*Glast iΔR3*) ([Figure 3](#F3){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}). The *Glast^CreERT2^* driver line allows the targeting of Glast^+^ NSCs that express *Vegfr3*. Restricted expression of Glast in glial cells excluded non-radial progenitor cells in the DG ([Figure S3A](#SD1){ref-type="supplementary-material"}; [@R15]; [@R56]). Mice were sacrificed 1 or 5 months after Tx treatment to test the effects of *Vegfr3* deletion in neurogenesis. Intercross of *Glast^CreERT2^* mice with ROSA26 and mT/mG reporter lines led to genetic recombination in \>65% of SGZ cells, indicating that *Glast-^creERT2^* likely drove mosaic deletion of *Vegfr3* in hippocampal NSCs ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}). Genetic recombination of *Vegfr3* locus was assessed by PCR in Tx-treated *Glast iΔR3* mice ([Figure S3C](#SD1){ref-type="supplementary-material"}). *Glast iΔR3* and control (*Vegfr3^flox/flox^*) animals were given a 3 hr BrdU pulse prior to sacrifice to label activated NSCs ([Figure 3A](#F3){ref-type="fig"}). One-month Tx-*Glast iΔR3* and control mice showed similar numbers of BrdU^+^ SGZ cells and DCX^+^ neuroblasts ([Figure 3B--3E](#F3){ref-type="fig"}). This result was expected because *Vegfr3* deletion occurs in Glast^+^ NSCs that rarely divide and slowly differentiate into DCX^+^ cells ([@R15]). In contrast, 5-month Tx-*Glast iΔR3* mice showed a 40% decrease in the number of BrdU^+^ NSCs and DCX^+^ neuroblasts compared to controls ([Figures 3B--3E](#F3){ref-type="fig"}). The number of GFAP^+^Nestin^+^ RGL cells and of astrocytes in the hilus was similar between controls and *Glast iΔR3* mice ([Figure 3F and 3G](#F3){ref-type="fig"}). The number of RGL cells was also not altered in *Glast iΔR3; Vegfr3::YFP* mice expressing YFP in RGL cells ([Figure S3D](#SD1){ref-type="supplementary-material"}). Altogether, these data indicate that decline of hippocampal neurogenesis in *Glast iΔR3* is not caused by a primary loss of NSCs or by an abnormal neuron/astrocyte differentiation balance. Anti-active caspase 3 antibody labeling and TUNEL staining of the DG showed only rare cells engaged in programmed cell death (PCD) in both Tx-control and -*Glast iΔR3* mice, indicating that *Vegfr3* deletion did not induce PCD in DG cells (data not shown). Therefore, *Vegfr3* loss of function in NSCs does not compromise NSC survival and renewal but selectively impairs NSC activation and conversion into proliferative IPCs.

Decline of hippocampal neurogenesis is associated with cognitive impairments and an enhancement of fear and anxiety in both mice and humans ([@R22]; [@R70]). We reasoned that decreased neurogenesis in 5-month Tx-*Glast iΔR3* mice might lead to behavioral defects. Five-month Tx-*Glast iΔR3* and -age-matched control mice were subjected to two paradigms to assess anxiety and locomotor activity: the elevated plus maze (EPM) test ([@R59]) and the open-field (OF) test ([@R29]), respectively ([Figures 3H, 3I](#F3){ref-type="fig"}, and [S3E--S3K](#SD1){ref-type="supplementary-material"}). Five-month Tx-*Glast iΔR3* mice displayed an anxiety phenotype in the EPM task, which was not due to a change in locomotor activity ([Figures 3H, 3I](#F3){ref-type="fig"}, and [S3E--S3K](#SD1){ref-type="supplementary-material"}). Altogether, these results suggest a VEGFR3-dependent correlation between the decline of hippocampal neurogenesis and an increase of fear/anxiety status that manifests in middle-aged mice.

VEGF-C/VEGFR3 Signaling Activates Hippocampal NSCs In Vivo {#S6}
----------------------------------------------------------

Because VEGF-C treatment drives NSC cell cycle entry in vitro, we investigated whether VEGF-C/VEGFR3 signaling also promoted NSC activation in vivo. VEGF-C was overexpressed during 2 to 3 weeks within the hippocampus of C57BLV6 adult mice by stereotaxic injection of adeno-associated virus (AAV) encoding full-length VEGF-C (AAV-VEGF-C) above the DG ([Figure 4A](#F4){ref-type="fig"}). AAV-EGFP was used as a control, and GFP expression in the hippocampal region showed that all animals had been efficiently infected ([Figure S4A](#SD1){ref-type="supplementary-material"}). VEGF-C induced a 2-fold increase in the number of BrdU^+^ SGZ cells compared to control ([Figure 4B](#F4){ref-type="fig"}). Consequently, the number of hippocampal DCX^+^ cells was increased, as shown at 5 weeks after AAV-VEGF-C injection ([Figure 4C](#F4){ref-type="fig"}). No changes in the density of DG capillaries were observed in AAV-VEGF-C-treated compared to control animals ([Figures S4B and S4C](#SD1){ref-type="supplementary-material"}). The effect of VEGF-C on NSC activation is therefore unlikely to be a secondary consequence of angiogenesis.

To determine whether VEGF-C acted specifically on *Vegfr3^YFP^* SGZ cells, AAV-VEGF-C was administered to adult *Vegfr3::YFP* mice. Two weeks following AAV-VEGF-C infection, BrdU^+^ *Vegfr3^YFP^* cells increased around 60% in number compared to AAV-EGFP-injected controls ([Figure 4D and 4E](#F4){ref-type="fig"}). Especially, the number of BrdU^+^ *Vegfr3^YFP^* RGL cells increased in AAV-VEGF-C-treated mice, suggesting that VEGF-C targets and activates quiescent *Vegfr3^YFP^* NSCs ([Figure 4F and 4G](#F4){ref-type="fig"}).

We expected that loss of *Vegfr3* function in NSCs should abolish the response to VEGF-C. AAV-VEGF-C or AAV-EGFP was delivered into the hippocampus of *Glast iΔR3* mice and controls 3 weeks after Tx injection ([Figure 4H](#F4){ref-type="fig"}). Two weeks later, Tx-treated control mice responded robustly to AAV-VEGF-C treatment by a significant increase in the number of BrdU^+^ NSCs. In contrast, VEGF-C overexpression failed to promote NSC proliferation in *Glast iΔR3* mice ([Figures 4I and 4J](#F4){ref-type="fig"}). VEGFR3 is therefore required for the response of hippocampal NSCs to VEGF-C, suggesting that VEGF-C/VEGFR3 signaling activates NSCs in vivo.

VEGFR3 Signaling Regulates Exercise-Induced Activation of Hippocampal NSCs {#S7}
--------------------------------------------------------------------------

We asked whether VEGF-C/VEGFR3 signaling controlled the NSC response to running activity, which promotes hippocampal NSC activation. First, we characterized the response of *Vegfr3^YFP^* cells ([Figure 5A](#F5){ref-type="fig"}). Running *Vegfr3::YFP* mice showed a robust increase in the number of BrdU^+^ *Vegfr3^YFP^* cells compared to sedentary controls ([Figure 5B](#F5){ref-type="fig"}). The total population of *Vegfr3^YFP^* cells was not increased ([Figure S5A](#SD1){ref-type="supplementary-material"}), but BrdU^+^ *Vegfr3^YFP^* cells significantly increased ([Figures 5B](#F5){ref-type="fig"} and [S5B](#SD1){ref-type="supplementary-material"}). Therefore, running activity promotes activation of *Vegfr3^YFP^* cells. This effect occurs in the absence of significant vascular remodeling ([Figures S5C--S5E](#SD1){ref-type="supplementary-material"}). As shown in [Figure S5F](#SD1){ref-type="supplementary-material"}, running activity had no significant effect on the level of *Vegfc* expression but increased *Vegfr3* transcript expression in the DG. *Vegfr3* expression likely amplifies in *Vegfr3^YFP^* cells because the number of these cells remained stable. Altogether, these data indicate that the running-activity-induced hippocampal neurogenesis involves the activation of *Vegfr3^YFP^* NSCs and the upregulation of *Vegfr3* expression in these cells.

To determine whether VEGFR3 was required for the exercise-induced activation of *Vegfr3^YFP^* NSCs, *Glast iΔR3* and control mice were housed with a running wheel for 3 weeks after Tx treatment ([Figure 5C](#F5){ref-type="fig"}). *Glast iΔR3* mice displayed a normal running activity with similar running distance compared to control mice ([Figure S5G](#SD1){ref-type="supplementary-material"}). However, *Glast iΔR3* mice were unable to activate running-induced neurogenesis, and the number of their BrdU^+^ SGZ cells was comparable with controls ([Figures 5D and 5F](#F5){ref-type="fig"}). In contrast, running still increased the number of DCX^+^ neuroblasts in *Glast iΔR3* mice similar to controls ([Figures 5E and 5G](#F5){ref-type="fig"}). A possible explanation for the lack of effect on the DCX^+^ cells is that the loss of NSCs in Tx-Glast iΔR3 mice might be compensated for by the increased proliferation of early neuroblasts (Tbr2^+^DCX^+^), which is known to be induced by running activity ([@R33]). Therefore, hippocampal NSC activation in response to running activity is VEGFR3 dependent but does not affect short-term production of newborn neurons.

VEGFR3 Activates ERK- and AKT-Signaling Pathways in Human NSCs {#S8}
--------------------------------------------------------------

To determine whether VEGFR3 signaling is conserved in human NSCs and to identify downstream targets of VEGFR3, we analyzed VEGFR3 expression and signaling pathways in cultures of NSCs derived from human embryonic stem cells (hESCs) (H1 and H9 cell lines). hESCs were differentiated into free-floating NSC-containing spherical neural masses (SNMs) ([Figure S6A--S6C](#SD1){ref-type="supplementary-material"}). Western blot and immunostaining analyses demonstrate that SNMs derived from either H9 or H1 hESCs express VEGFR3, but not VEGFR2 ([Figure 6A, 6B](#F6){ref-type="fig"}, and [S6D](#SD1){ref-type="supplementary-material"}). VEGFR3^+^ cells display elongated cytoplasmic processes that correspond mainly to BLBP-positive NSCs, but not DCX neuroblasts, under both 3D- and flat-culture conditions ([Figure 6C](#F6){ref-type="fig"} and [S6E](#SD1){ref-type="supplementary-material"}).

hNSC treatment with VEGF-C stimulates cell division ([Figure 6D](#F6){ref-type="fig"}). The mitotic response to VEGF-C is preceded by a rapid induction of VEGFR3 phosphorylation ([Figure 6E](#F6){ref-type="fig"}). VEGF-C also strongly activates intracellular signals including ERK and AKT phosphorylation ([Figure 6F](#F6){ref-type="fig"}). At a later time point (15 min), VEGF-C treatment stimulates AKT-downstream-signaling pathways including glycogen synthase kinase 3β (GSK3β) ([Figure 6F](#F6){ref-type="fig"}). GSK3β is inhibited by pAKT and regulates cell cycle entry, cell proliferation, and cell fate ([@R35]). MAZ51, an indolinone that blocks VEGFR-3 signaling ([@R42]), inhibits VEGF-C-induced AKT phosphorylation in hESC-derived NSCs ([Figure S6F](#SD1){ref-type="supplementary-material"}). Therefore, VEGF-C/VEGFR3 regulates downstream signals controlling NSC activation, providing a molecular explanation for the NSC behavioral changes observed following VEGF-C/VEGFR3 signaling manipulation.

DISCUSSION {#S9}
==========

We here identify a growth-factor-receptor-signaling pathway that promotes NSC activation during hippocampal neurogenesis. We show that *Vegfr3* is expressed by mouse hippocampal NSCs and that VEGF-C/VEGFR3 signaling is necessary for activation and conversion of NSCs into progenitor cells. Furthermore, we demonstrated that VEGF-C/VEGFR3 signaling is evolutionarily conserved in human NSCs, where it promotes cell proliferation and activates ERK/AKT pathways. To our knowledge, VEGF-C/VEGFR3 is the first known growth-factor-signaling pathway that selectively promotes NSC activation, suggesting that VEGF-C could be therapeutically used to enhance neurogenesis in humans.

We found that, like type-B'astrocytes of the SVZ ([@R12]), hippocampal NSCs exhibit *Vegfr3^YFP^* reporter expression and a specific enrichment of *Vegfr3* transcripts. Expression of YFP in all RGL cells and the exclusive generation of neurospheres from *Vegfr3^YFP^* DG cells strongly suggest that *Vegfr3* is characteristic for hippocampal NSCs. The *Vegfr3::YFP* mouse adds to the few models of transgenic reporter lines, such as *Nestin*- ([@R17]; [@R23]) and *Hes5*-reporter mice ([@R51]), allowing the detection and sorting of adult NSCs. The level of YFP reporter expression was much higher in NSCs than progenitors, indicating that *Vegf3* is downregulated along with the asymmetric cell division of activated NSCs into progenitor cells.

Three independent lines of evidence demonstrate a direct requirement of VEGFR3 in NSC activation. First, VEGF-C treatment of *Vegfr3^YFP^* cells, but not *Vegfr3^YFP-negative^* cells, activates cell cycle entry; second, genetic deletion of *Vegfr3* in NSCs impairs neurogenesis; and third, VEGF-C-induced NSC activation is lost in *Vegfr3* mutant mice. *Vegfr3* deletion in NSCs decreases the populations of activated NSCs and neuroblasts, without affecting the pool of NSCs in middle-aged mice. VEGFR3 activity is therefore not necessary for NSC maintenance but required for the generation of progenitors and neuroblasts, suggesting that VEGF-C/VEGFR3 signaling regulates activation of cell division in NSCs. This hypothesis is reinforced by RNA-seq data showing that VEGF-C stimulation shifts NSCs from their undifferentiated state toward a proliferating progenitor state. VEGF-C/VEGFR3 signaling in NSCs downregulates the expression of Bmi-1 and Rest, which interact with a broad array of transcriptional and epigenetic regulatory cofactors to maintain sternness and inhibit NSC differentiation ([@R2]; [@R25]). This suggests that activation of VEGFR3 by VEGF-C de-represses the NSC differentiation program. VEGF-C/VEGFR3 signaling in NSCs is also characterized by upregulated expression of factors that are mandatory checkpoint regulators of the cell cycle. Although novel in the context of NSCs, this finding is not surprising when viewed from an angiogenesis perspective. VEGF-C is a well-known mitogen for VEGFR3^+^ lymphatic endothelial cells and mediates downstream signaling through activation of ERK and AKT ([@R43]), which suggests that these downstream signaling events are conserved between endothelial cells and NSCs.

The sources of VEGF-C for inducing NSC activation as well as the mechanisms regulating Vegfr3 expression in NSCs remain to be determined. NSCs contain *Vegf-c* transcripts, suggesting that, besides paracrine VEGF-C from DG cells, autocrine VEGF-C may activate VEGFR3 at the cell membrane. The discontinuous process of NSC activation also implies that VEGF-C availability may be regulated by translational or post-translational processes in NSC, perhaps through control of VEGF-C maturation by enzymes such as CCBE1 (collagen- and calcium-binding epidermal growth factor domains 1) ([@R46]). NSC activation is moreover likely to be controlled by a tight regulation of VEGFR3 expression levels. We found that *Vegfr3* expression in DG cells is physical activity dependent, suggesting that it could be regulated by activity-dependent epigenetic mechanisms, such as DNA methylation that modulates neurogenesis ([@R31]; [@R38]; [@R64]) and also controls *Vegfr3* expression in endothelial cells ([@R62]). Notch signaling is another regulator that inhibits VEGFR3 expression in endothelial cells ([@R7]), suggesting that Notch may maintain NSCs quiescence by regulating *Vegfr3* expression. Conversely, we show that VEGFR3 activation in NSCs downregulates Notch and its downstream targets, suggesting that functional antagonism between VEGFR3 and Notch could switch NSC fate from quiescence to activation. Interestingly, *Notch1* deletion in NSCs ([@R1]) induces similar phenotype to *Vegfr3* deletion in NSCs, i.e., a delayed reduction in the populations of dividing NSPCs and neuroblasts.

Another novelty of our study is the finding that VEGFR3 expression is conserved in human NSCs, where it promotes proliferation and regulates ERK and AKT, GSK3β signaling cascades in response to VEGF-C. Through VEGFR3, VEGF-C activates several downstream signaling cascades promoting transcription, such as ERK for mitogen-stimulated proliferation ([@R61]), and translation, such as mTOR and S6K signals, which regulate cell survival and cell fate decisions ([@R10]; [@R35]). VEGF-C is therefore able to rapidly and simultaneously regulate cell cycle entry and differentiation processes in NSCs, which likely explains its potent role in mouse hippocampal neurogenesis.

We found that, in addition to impaired neurogenesis, Tx-*Glast iΔR3* showed increased anxiety behavior, suggesting that VEGFR3 signaling in DG NSCs may contribute to emotional response. Although further research is required to reinforce this finding, it confirms previous genetic evidence that manipulation of neurogenesis alters behavior in models of anxiety and depression ([@R21]; [@R30]; [@R65]; [@R66]). However, VEGFR3 is expressed by other Glast-expressing cells besides hippocampal NSCs, including tanycytes in the hypothalamic median eminence and a few astrocytes in the amygdala ([@R34]; [@R63]). These regions are involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis that controls reactions to stress as well as mood and emotions ([@R13]), suggesting that VEGFR3 signaling in NSC/astrocytes may act on behavior by modulating the functioning of the limbic-HPA axis.

VEGF-C can promote angiogenesis ([@R27]) but only weakly when compared to VEGF-A, because VEGFR3-signaling activity is mainly restricted to sprouting tip cells and inhibited in other endothelial cells by Notch signaling ([@R69]). VEGF-C may thus be a candidate factor to enhance NSC activation, without unwanted effects on other cell types. Altogether, our findings are consistent with the possibility that VEGF-C activation of NSCs could improve age-related decline in hippocampal neurogenesis and associated mood defects, such as those seen in Alzheimer's disease.

EXPERIMENTAL PROCEDURES {#S10}
=======================

Animals {#S11}
-------

C57/BI6 mice (Jackson Laboratories) were maintained in the Animal Research Center at Yale University. The *Vegfr3::YFP* ([@R12]), *Glast^creERT2^, Vegfr3^flox/flox^* ([@R32]), and Vegf-*c^Lacz/+^* ([@R39]) mice have been described previously. *Glast^CreERT2^* mice were crossed with *Vegfr3^flox/flox^* mice to generate NSC-specific and Tx-inducible *Vegfr3* mutant mice (*Glast iΔR3*). Animals were sacrificed the days indicated in each experiment. All experiments were approved by the IACUC of Yale University.

TX Treatment {#S12}
------------

To induce genetic recombination, 2-month-old adult mice were injected intraperitoneally (i.p.) with tamoxifen (TX) once per day for 10 consecutive days (as indicated in the experiments) at a dose of 2 mg per day.

BrdU Administration {#S13}
-------------------

BrdU (Sigma) was administered to the adult animals via a single i.p. injection (300 mg/kg) 3 hr before sacrifice. The brains were processed for immunohistochemistry as described below.

Tissue Collection and Immunohistochemistry {#S14}
------------------------------------------

Animals were anesthetized with isoflurane inhalation and perfused first with PBS and then with 4% paraformaldehyde (PFA). Brains were post-fixed overnight in 4% PFA and then washed with PBS. Brain coronal vibratome sections (40 µm) of brains were incubated with serum-free blocking solution (DAKO) for 1 hr at 4°C and then incubated overnight at 4°C with the primary Ab (listed in [Table S1](#SD1){ref-type="supplementary-material"}) diluted in PBS containing 0.1% Triton X-100 (PBST). After washing, sections were incubated with the corresponding conjugated secondary. For immunolabeling of SNMs, cryosections (20 µm) were then performed and stained as indicated above. DAPI was used for nucleus counterstaining.

β-Galactosidase Staining {#S15}
------------------------

Sections were immersed in 10 mM Tris-HCI (pH 7.3) containing 0.005% Na-deoxycholate, 0.01% Nonidet P40, 5 mM ferrocyanide, 5 mM ferricyanide, 2 mM MgCl~2~, and 1 mg/ml X-gal at 37°C until the signal became visible.

Q-PCR {#S16}
-----

*Vegfr3::YFP* mice (total 108 mice) were used for FACS and further Q-PCR analysis of *Vegfr3^YFP^* cells. RNA was isolated from sorted cells using the Nucleo-Spin RNA XS (Macherey-Nagel) and from tissues using RNeasy lipid tissue kit (QIAGEN). Real-time quantitative PCR reactions were performed in duplicate using the CFX-96 Real Time PCR system (Bio-Rad). Primers (Quantitect primer assays) were purchased from QIAGEN.

FACS {#S17}
----

The DG was carefully isolated from the hippocampus; treated with papain (0.8 mg/ml; Worthington) for 30 min at 37°C; and then mechanically dissociated in PBS containing 5% FCS, 0.3% glucose, and 5 mM HEPES in order to obtain a single-cell suspension. Dissociated cells were stained with anti-CD31 Ab to exclude endothelial cells. Aria was used for sorting with the DIVA software (BD Biosciences).

Cell Cultures {#S18}
-------------

FACS-sorted cells were plated at 1 × 10^4^ cells/well in 24-well plates. Neurospheres were grown in Complete Culture Medium (CCM) (DMEM/F12-Glutamax \[GIBCO\], 20 µg/ml insulin \[Sigma\], 1/200 B-27 supplement \[GIBCO\], 1/100 N-2 supplement \[GIBCO\], 0.3% glucose, 5 mM HEPES, and 100 U/ml of penicillin/streptomycin) enriched with 20 ng/ml bFGF and 20 ng/ml EGF (both from Peprotech) during 10 days in vitro (DIV). To analyze cell differentiation, mechanically dissociated 10-DlV-derived neurospheres were plated onto Matrigel-coated glass coverslips in CCM without EGF/bFGF for 7 DIV. To test the effect of VEGF-C on neurosphere formation and cell survival, cells were plated in CCM containing EGF and bFGF alone or with recombinant rat VEGF-C (50 ng/ml; Reliatech) and rat 31C1- IgG2a antibodies (5 µg/ml; Imclone). Neurosphere formation was scored at 5 DIV by counting the number of neurospheres in culture. For survival assay, cells were incubated overnight on glass coverslips with or without VEGF-C (50 ng/ml), fixed, and labeled with the TUNEL detection kit (Roche 11 684 809 910).

Intra-cerebral Stereotaxic Injections {#S19}
-------------------------------------

Animals were anesthetized with isoflurane, and skull holes were drilled overlying the hippocampus on both hemispheres. The site of infusion was at the following coordinates relative to bregma: anteroposterior, −1.8 mm; mediolateral, −1.8 mm; and dorsoventral, −1.8 mm. Two microliters of control AAV-EGFP (control) or AAV-VEGF-C were infused at a flow rate of 0.5 µl/min. Two to three weeks after injection, the brains were processed for immunohistochemistry as described.

Stereological Analysis {#S20}
----------------------

The marker (BrdU, DCX, and YFP)-positive cells were counted in a one-in-six series of five sections (40 µm, 240 mm apart) throughout the rostrocaudal extent of the dorsal DG. The sections stained with DAPI were used to measure DG area using Volocity software (PerkinElmer). The total number of marker^+^ cells was determined by summing the number of marker^+^ cells and multiplying this number of cells by the number of serial sections (number of cells/series x 6). Total volume was determined by summing the traced DG areas for each section multiplied by the distance between sections sampled (area x 240 µm). To calculate the number of marker^+^ cells per volume (1 mm^3^), the total number of marker^+^ cells was divided by the total volume.

hESC-Derived NSC Cultures {#S21}
-------------------------

We have progressively differentiated hESCs into free-floating SNMs that contain self-renewing, multipotent NSCs according to a protocol ([@R14]). All experiments have been performed on SNMs derived from two different H1 (male) and H9 (female) hESC lines ([@R4]). Detailed information is provided in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Statistics {#S22}
----------

A two-tailed, unpaired Student's t test or Mann-Whitney test were done to determine statistical significance (Graph-Pad Prism 6). Differences were considered statistically significant if the p value was 0.05 (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.005). Error estimates were displayed as SEM.

Supplementary Material {#SM}
======================
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According to the MIAME guidelines, all transcriptornic data were submitted to a MIAME compliant repository, NCBI's Gene Expression Omnibus (GEO), and are accessible through the GEO accession number GSE55621.
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![*Vegf-c/Vegfr3* Are Expressed by Adult Hippocampal Stem Cells\
(A) Coronal DG section of an adult *Vegfr3::YFP* mouse. YFP expression is detected both in vessels and SGZ cells. White dotted line indicates SGZ.\
(B) isolation of *Vegfr3^YFP^* cells from the DG of adult *Vegfr3::YFP* mice. After exclusion of CD31^+^ endothelial cells, a subset of *Vegfr3^YFP^* cells were sorted by FACS.\
(C) qRT-PCR analysis of FACS-sorted cells from the DG of *Vegfr3::YFP* adult mice. *Vegfr3* transcripts are specifically enriched in *Vegfr3^YFP^* cells compared to total DG neural cells (non-endothelial DG cells) and *Vegfr3^YFP-negative^* cells, n = 3 independent experiments; bars: mean ± SEM; Student's t test: p \< 0.05 (\*).\
(D and E) Coronal DG section of adult *Vegfc^lacZ/+^* mouse stained with X-gal and of wild-type mouse labeled with anti-VEGF-C Ab (E). White arrows indicate a higher level of VEGF-C expression in SGZ.\
(F) Representative images of coronal DG sections in adult *Vegfr3::YFP* mice stained with Abs against markers of RGL (GFAP and Nestin), progenitor cells (Ascl1 and Tbr2), neuroblasts (DCX), and neurons (NeuN) (red).\
(G) Quantification of *Vegfr3^YFP^* SGZ cells by their morphology. Percentage of *Vegfr3^YFP^* RGL cells expressing GFAP and Nestin.\
(H) Quantification of *Vegfr3^YFP^* SGZ cell subtypes according to their antigen expression. y axis: % of YFP^+^ marker^+^ cells/YFP^+^ cells. Total 30--500 cells were counted from three to six sections.\
(I) 5% of *Vegfr3^YFP^* SGZ cells has entered the cell cycle (Ki67^+^). n = 100--150 cells/section, counted from seven sections. Bars: mean ± SEM.\
(J) *Vegfr3^YFP^* cells represent 60% of BrdU^+^ SGZ cells. Most BrdU^+^*Vegfr3^YFP^* cells are non-radial cells (98%), and only a few of them are RGL cells (2%). n = 30--50 cells counted from five sections.\
(K) *Vegfr3^YFP^* SGZ cell morphology and activity. An anti-GFAP Ab labels RGLs (white), but not YFP^+^-non-radial cells. A 3-hr pulse of BrdU (red) labels exclusively non-radial YFP^+^ cells.\
(L) Comparison of the expression of *Vegfr3^YFP^* and other stage-specific markers in SGZ cells. *Vegfr3^YFP^* expression is specific to NSCs and progenitor cells.\
The scale bars represent 100 µm (A, D, and E) and 16 µm (F and K).\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms743270f1){#F1}

![VEGF-C/VEGFR3 Signaling Activates Hippocampal NSCs In Vitro\
(A and B) Neurosphere cultures derived from sorted *Vegfr3^YFP^* and *Vegfr3^YFP-negative^*cells. The formation of neurospheres was only observed in *Vegfr3^YFP^* cell cultures that can self-renew for at least six successive passages.\
(C) Representative images and quantification of neurosphere differentiation. *Vegfr3^YFP^* cells differentiate into TuJ1^+^ neuron (green), GFAP^+^ astrocyte (blue), and very few 04^+^ oligodendrocyte (red).\
(D) Cell death was quantified by TUNEL staining.\
(E) Representative images and quantification of neurospheres after treatment with VEGF-C (50 ng/ml) and a VEGFR3-function-blocking antibody (31C1).\
(F) FACS profile and cell cycle analysis of control *Vegfr3^YFP^* cells and VEGF-C-treated *Vegfr3^YFP^* cells after *Pyronin Y/Hoechst* 33342 staining. The scale bars represent 50 µm (A and C).\
Student's t test: p \< 0.05 (\*); p \< 0.005 (\*\*); not significant (ns). Bars: mean ± SEM; n = 3--5 independent experiments. See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms743270f2){#F2}

![*Vegfr3* Deletion in Adult Hippocampal NSPCs\
(A) Schedule of Tx and BrdU administration to induce *Vegfr3* deletion in NSCs and label-activated NSCs.\
(B and C) Representative images of coronal DG sections from control (upper panel) and *Glast iΔR3* mice (lower panel) at indicated time points. Sections are stained for BrdU (red), DAPI (blue), and DCX (green). The scale bars represent 70 µm.\
(D and E) Quantification of BrdU^+^ cells and DCX^+^ cells in the DG of control and *Glast iΔR3* mice at 1 month and 5 months post-Tx administration.\
(F and G) Representative images and quantification of RGL cells (GFAP^+^Nestin^+^ cells in SGZ, white arrow) and astrocytes (GFAP^+^ cells in hilus) of control and *Glast iΔR3* mice at 5 months post-Tx administration. The scale bars represent 16 µm.\
(H and I) Quantification of and EPM test.\
Student's t test: p \< 0.05 (\*); not significant (ns). Bars: mean ± SEM.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms743270f3){#F3}

![VEGFR3 Mediates VEGF-C-Induced Proliferation in Hippocampal NSCs\
(A) Intra-hippocampal injection of AAV~9~-GFP (control) and -VEGF-C. At 2 to 3 weeks after AAV infection, mice were given a 3-hr pulse of BrdU and analyzed to quantify proliferation and neuroblast production in the DG.\
(B and C) Quantification of BrdU^+^ cells and DCX^+^ cells in the SGZ of control and VEGF-C-treated mice.\
(D and E) Representative images and quantification of BrdU^+^*Vegr3^YFP^* cells after VEGF-C overexpression in *Vegfr3::YFP* mice. VEGF-C treatment increases BrdU^+^*Vegr3^YFP^* cells in SGZ (white arrows). The scale bars represent 35 µm.\
(F and G) Representative images and quantification of BrdU^+^*Vegr3^YFP^* RGL cells after VEGF-C overexpression in *Vegfr3::YFP* mice. VEGF-C treatment increases BrdU^+^*Vegr3^VFP^* RGL cells in SGZ (white arrows). The scale bars represent 35 µm.\
(H) Schedule of Tx treatment, AAV~9~ infection, and BrdU administration in control and *Glast iΔR3* mice.\
(I and J) Representative images and quantification of BrdU^+^ SGZ cells in control (upper panel) and -*Glast iΔR3* mice (lower panel) after VEGF-C treatment. VEGF-C overexpression increases BrdU^+^ SGZ cells (red) in control mice, but not in *Glast iΔR3* mice. The scale bar represents 35 µm.\
Student's t test: p \< 0.05 (\*); ns, not significant. Bars: mean ± SEM.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms743270f4){#F4}

![VEGFR3 Is Required for Exercise-Induced NSPC Proliferation\
(A) Schedule of voluntary running activity and BrdU administration for *Vegfr3::YFP* mice.\
(B) Quantification of BrdU^+^ cells and *BrdU^+^Vegfr3^YFP^* cells in the SGZ of sedentary control and running *Vegfr3::YFP* mice.\
(C) Schedule of Tx treatment, voluntary running activity, and BrdU administration in control and *Glast iΔR3* mice.\
(D--G) Representative images and quantification of BrdU^+^ SGZ cells and DCX^+^ cells in control (upper panel) and *Glast iΔR3* mice (lower panel), either sedentary (left) or running (right). BrdU^+^ cells (red), DAPI (blue), and DCX^+^ cells (green) are shown. Running induces proliferation of NSCs in control mice, but not in *Glast iΔR3* mice. A similar number of neuroblasts is generated in control and *Glast iΔR3* mice. The scale bar represents 35 µm. Student's t test: p \< 0.05 (\*); p \< 0.001 (\*\*\*); not significant (ns). Bars: mean ± SEM. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms743270f5){#F5}

![VEGFR3-Signaling Pathway in Human NSCs\
(A) Western blot analysis of VEGFR2 and VEGFR3 expression in H1 human-ESC-derived NSCs. *VEGFR3* migrates as *three molecular weight* species: 195,175, and 125 kDa (arrows). EB, embryoid bodies; ESC, embryonic stem cells; HUVEC, human umbilical vein endothelial cells; NP, neural progenitors; SNM, spherical neural mass.\
(B) SNMs stained with anti-hVEGFR2 and -hVEGFR3 antibodies as indicated. The scale bars represent 100 µm.\
(C) SNMs stained for VEGFR3 (green), BLBP (red; astroglia/NSC), or DCX (red; neuron) and DAPI (gray). The scale bars represent 20 µm.\
(D) Representative image of phospho-histone H3 staining. The scale bar represents 100 µm.\
(E) Phospo-VEGFR3 analysis by immunoprecipitation.\
(F) Western blot analysis of the phosphorylation state of ERK, AKT (tyrosine 398 and serine 473), and GSK3β in SNMs after VEGF-C stimulation. Student's t test: p \< 0.05 (\*). Bars/lines: mean ± SEM.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms743270f6){#F6}

###### Highlights

-   VEGFR3 is required for adult hippocampal neurogenesis

-   VEGFR3 signaling converts quiescent neural stem cells into progenitor cells

-   VEGF-C/VEGFR3 activates human neural stem cells through ERK and AKT
